Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
After two years of dedicated and persistent advocacy by ADI, dementia will, for the first time, be formally recognised within the new UN Political Declaration on noncommunicable diseases (NCDs) and mental health, as a leading NCD.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Perceptions of dementia are dependent on many factors, such as direct personal experience with a loved one having the condition or exposure to public information campaigns, for example. Popular culture also plays a role in shaping the public discourse around dementia in ways that can have significant consequences on the…
The National Institute for Health and Care Excellence (NICE) has concluded that the benefits from two treatments for early Alzheimer's Disease, donanemab and lecanemab, remain too small to justify the additional cost. Consequently, free access to these Alzheimer's treatments will not be provided in the UK.
Challenging dementia stigma is one of ADI’s core missions, and one where there is unfortunately still a long way to go. ADI’s global survey on attitudes to dementia in 2024 revealed that a worrying 80% of the general public still thinks that dementia is a normal part of ageing,…
In May, ADI’s Regional Director for the Asia Pacific Region, DY Suharya travelled to Sydney, Australia to participate in the launch of the e-DiVA programme alongside representatives from Australia, New Zealand, Indonesia, and Viet Nam. Then, ADI Board Member and Executive Vice President of ADI member Alzheimer’s Disease Chinese, Professor Huali Wang, was one of the six public health champions celebrated at the 78th World Health Assembly later in the month.
From in-person high level engagements in Lima to Buenos Aires, to a digital campaign partnership providing regionally specific resources, May has proven to be an action-packed month in the Americas region. ADI Regional Director for the America’s provides his highlights from across the region including advocacy work in Argentina and Peru, alongside a public awareness campaign in partnership with the Carlos Slim Foundation.
Marketing authorisation has been granted for donanemab (Kisunla) in Australia, following announcements from Brazil, and Mexico, for the treatment of Alzheimer's disease. The authorisations in Brazil and Mexico were granted in April 2025, with the announcement of the Australian approval on 21 May 2025.
On 29 April 2025, ADI Regional Director for the Americas, Diego Aguilar attended the Symposium on Brain Health Promotion: Towards a National Dementia Plan in Buenos Aires, Argentina, during which key political figures, international experts, civil society leaders, and advocates joined the call for the urgent approval of Argentina’s first National Dementia Plan.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.